enteralogo.png
Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy
May 16, 2022 08:00 ET | Entera Bio Ltd.
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of...
enteralogo.png
Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights
May 12, 2022 08:00 ET | Entera Bio Ltd.
Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underwayCompany reschedules conference call...
enteralogo.png
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics
May 05, 2022 08:00 ET | Entera Bio Ltd.
— Inventions aim to improve bioavailability and reduce drug costs — — Patent applications include optimized oral delivery of specific molecules for various indications — BOSTON and JERUSALEM, May ...
enteralogo.png
Entera Bio to Report First Quarter 2022 Financial Results on May 12
April 28, 2022 08:00 ET | Entera Bio Ltd.
BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report...
MBX Logos FINAL FULL.jpg
MBX Biosciences Appoints Richard B. Bartram as Chief Financial Officer
April 11, 2022 07:30 ET | MBX Biosciences, Inc.
CARMEL, Ind., April 11, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing peptide therapeutics with a focus on the treatment of endocrine...
MBX Logos FINAL FULL.jpg
MBX Biosciences Appoints Ora Hirsch Pescovitz, M.D., to Board of Directors
April 05, 2022 08:00 ET | MBX Biosciences, Inc.
CARMEL, Ind., April 05, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing peptide therapeutics with a focus on the treatment of endocrine...
enteralogo.png
Entera Bio to Present at 2022 Maxim Virtual Growth Conference
March 22, 2022 08:00 ET | Entera Bio Ltd.
BOSTON and JERUSALEM, March 22, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the Company...
enteralogo.png
Entera Bio Reports Financial Results for the Year Ended December 31, 2021
March 08, 2022 06:30 ET | Entera Bio Ltd.
— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 —— New EB612 formulation for Hypoparathyroidism trial planned in 2022 —— Oral delivery technology platform advances with more...
enteralogo.png
Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022
March 03, 2022 09:50 ET | Entera Bio Ltd.
BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report...
Logo 1.png
Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
May 06, 2021 08:05 ET | Aeterna Zentaris Inc
 –In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical...